{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:22:31Z","timestamp":1789129351073,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["79\/159\/2015\/NCD-III"],"award-info":[{"award-number":["79\/159\/2015\/NCD-III"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["2017\\u201319"],"award-info":[{"award-number":["2017\\u201319"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012913","name":"Tata Consultancy Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012913","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Southeast Asia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.lansea.2025.100710","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T16:17:12Z","timestamp":1767370632000},"page":"100710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Functional precision approach in patients with very high risk acute lymphoblastic leukaemia in India: a single-centre cohort study"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5926-5167","authenticated-orcid":false,"given":"Jasmeet","family":"Sidhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0190-1831","authenticated-orcid":false,"given":"Arijit","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parag","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio D.","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2741-5229","authenticated-orcid":false,"given":"Subhajit","family":"Kundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangramjit","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaswati","family":"Tarafdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanima","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhirupa","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mousumi","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Sivadasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritha","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niharendu","family":"Ghara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Bornhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bourquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shekhar","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2916-9649","authenticated-orcid":false,"given":"Vaskar","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.lansea.2025.100710_bib1","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/blood-2013-10-532598","article-title":"Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study","volume":"123","author":"Conter","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.lansea.2025.100710_bib2","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lansea.2025.100710_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(15)70082-3","article-title":"Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study","volume":"16","author":"Pui","year":"2015","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.lansea.2025.100710_bib4","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1182\/blood-2016-12-725804","article-title":"Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia","volume":"129","author":"Campana","year":"2017","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.lansea.2025.100710_bib5","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/Phase II Study of blinatumomab in pediatric patients with Relapsed\/Refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.lansea.2025.100710_bib6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lansea.2025.100710_bib7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s43058-022-00310-5","article-title":"Evaluating blinatumomab implementation in low- and middle-income countries: a study protocol","volume":"3","author":"Duffy","year":"2022","journal-title":"Implement Sci Commun"},{"issue":"11","key":"10.1016\/j.lansea.2025.100710_bib8","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","article-title":"Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia","volume":"129","author":"Frismantas","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lansea.2025.100710_bib9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13063-022-06033-1","article-title":"Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India","volume":"23","author":"Das","year":"2022","journal-title":"Trials"},{"issue":"7","key":"10.1016\/j.lansea.2025.100710_bib10","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3324\/haematol.2023.283148","article-title":"TCF3::HLF acute lymphoblastic leukemia: still challenging to cure thirty years later","volume":"108","author":"Tasian","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.lansea.2025.100710_bib11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood-2016-10-743765","article-title":"Near-haploid and low-hypodiploid acute lymphoblastic leukemia: two distinct subtypes with consistently poor prognosis","volume":"129","author":"Safavi","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.lansea.2025.100710_bib12","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","article-title":"IKZF1(plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-Cell precursor acute lymphoblastic leukemia","volume":"36","author":"Stanulla","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lansea.2025.100710_bib13","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"4","author":"Yadav","year":"2014","journal-title":"Sci Rep"},{"issue":"9596","key":"10.1016\/j.lansea.2025.100710_bib14","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.lansea.2025.100710_bib15","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/2159-8290.CD-19-1059","article-title":"Relapse-Fated latent diagnosis subclones in acute B lineage leukemia are drug tolerant and possess distinct metabolic programs","volume":"10","author":"Dobson","year":"2020","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.lansea.2025.100710_bib16","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/bjh.16005","article-title":"Efficacy and safety of a bortezomib and reduced-intensity cytarabine-based protocol, TMC ALLR1, for relapsed childhood ALL in India","volume":"186","author":"Roy","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.lansea.2025.100710_bib17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41591-022-02112-7","article-title":"Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.lansea.2025.100710_bib18","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3324\/haematol.2022.281443","article-title":"Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia","volume":"108","author":"Pariury","year":"2023","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.lansea.2025.100710_bib19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/bloodadvances.2024014405","article-title":"Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia","volume":"9","author":"Luskin","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.lansea.2025.100710_bib20","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/bloodadvances.2023012231","article-title":"A phase 1\/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"8","author":"Short","year":"2024","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.lansea.2025.100710_bib21","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.clinthera.2024.09.008","article-title":"Dosing of venetoclax in pediatric patients with relapsed acute myeloid leukemia: analysis of developmental pharmacokinetics and exposure-response relationships","volume":"46","author":"Badawi","year":"2024","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.lansea.2025.100710_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31630","article-title":"Venetoclax combined with chemotherapy in pediatric and adolescent\/young adult patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"72","author":"Place","year":"2025","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.lansea.2025.100710_bib23","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ccell.2024.03.003","article-title":"Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia","volume":"42","author":"Huang","year":"2024","journal-title":"Cancer Cell"},{"issue":"Suppl 3","key":"10.1016\/j.lansea.2025.100710_bib24","doi-asserted-by":"crossref","first-page":"S222","DOI":"10.3816\/CLM.2009.s.016","article-title":"High-risk childhood acute lymphoblastic leukemia","volume":"9 Suppl 3","author":"Bhojwani","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"25","key":"10.1016\/j.lansea.2025.100710_bib25","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1200\/JCO.22.02705","article-title":"Improved outcome for ALL by prolonging therapy for IKZF1 deletion and decreasing therapy for other risk groups","volume":"41","author":"Pieters","year":"2023","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.lansea.2025.100710_bib26","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood.2024027270","article-title":"Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome","volume":"145","author":"Chen","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.lansea.2025.100710_bib27","first-page":"1","article-title":"Venetoclax-based regimen in refractory or relapsed pediatric acute lymphoblastic leukemia","author":"Zhang","year":"2025","journal-title":"Acta Haematol"},{"issue":"40","key":"10.1016\/j.lansea.2025.100710_bib28","doi-asserted-by":"crossref","first-page":"43048","DOI":"10.18632\/oncotarget.5528","article-title":"Stromal cell-mediated mitochondrial redox adaptation regulates drug resistance in childhood acute lymphoblastic leukemia","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.lansea.2025.100710_bib29","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1200\/JCO.21.02678","article-title":"Children's oncology group trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-Cell acute lymphoblastic leukemia and lymphoma","volume":"40","author":"Teachey","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.lansea.2025.100710_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29046","article-title":"Unsatisfactory quality of E. coli asparaginase biogenerics in India: implications for clinical outcomes in acute lymphoblastic leukaemia","volume":"68","author":"Sidhu","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.lansea.2025.100710_bib31","article-title":"Risk stratified treatment for childhood acute lymphoblastic leukaemia: a multicentre observational study from India","volume":"37","author":"Gogoi","year":"2025","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"4","key":"10.1016\/j.lansea.2025.100710_bib32","first-page":"1253","article-title":"BH3 profiling as pharmacodynamic biomarker for the activity of BH3 mimetics","volume":"109","author":"Pan","year":"2024","journal-title":"Haematologica"}],"container-title":["The Lancet Regional Health - Southeast Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772368225001817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772368225001817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:01:00Z","timestamp":1773950460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772368225001817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"alternative-id":["S2772368225001817"],"URL":"https:\/\/doi.org\/10.1016\/j.lansea.2025.100710","relation":{},"ISSN":["2772-3682"],"issn-type":[{"value":"2772-3682","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional precision approach in patients with very high risk acute lymphoblastic leukaemia in India: a single-centre cohort study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Southeast Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lansea.2025.100710","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100710"}}